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Summary
Background: The real-world, long-term benefits of sustained virologic response (SVR) on the 
risk of variceal bleeding remain unclear.
Aim: We aimed to assess the association between DAA-induced SVR and post-treatment variceal 
bleeding.
Methods: We identified patients who initiated DAA-only antiviral treatments in the Veterans 
Affairs healthcare system from 2013–2015. We followed patients until 01/01/2019 for the 
development of gastroesophageal variceal bleeding defined by diagnostic codes. We used 
multivariable Cox proportional hazards regression to assess the association between SVR and 
development of variceal bleeding, adjusting for potential confounders.
Results: Among 33,582 DAA-treated patients, 549 (1.6%) developed variceal bleeding after 
treatment (mean follow-up 3.1 years). Compared to no-SVR, SVR was associated with a 
significantly lower incidence of variceal bleeding among all patients (0.46 vs. 1.26 per 100-patient 
years, adjusted hazard ratio [AHR] 0.66, 95% CI 0.52–0.83), among patients with pre-treatment 
cirrhosis (1.55 vs 2.96 per 100 patient-years, AHR 0.73, 95% CI 0.57–0.93) and among patients 
without pre-treatment cirrhosis (0.07 vs. 0.29 per 100 patient-years, AHR 0.33, 95% CI 0.17–
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0.65). The risk of variceal bleeding after treatment was lower in those who achieved SVR versus 
no SVR among patients who had non-bleeding varices (3.5 vs 4.9 per 100 patient-years) or 
bleeding varices (12.9 vs 16.4 per 100 patient-years) diagnosed before treatment, but these 
differences were not statistically significant in adjusted analyses.
Conclusion: DAA-induced SVR is independently associated with lower risk of variceal bleeding 
during long-term follow-up in patients with and without pre-treatment cirrhosis. These findings 
demonstrate an important real-world benefit of DAA treatment.
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Introduction
Gastrooesophageal varices are a common complication of cirrhosis that can lead to 
substantial morbidity and mortality1–3. Hepatitis C virus (HCV) infection is a leading cause 
of cirrhosis in the US4. With the advent of direct-acting antiviral agents (DAA), HCV cure 
rates have increased dramatically and the majority of patients with HCV are now expected to 
achieve sustained virologic response (SVR)5. Furthermore, SVR can now be achieved in the 
majority of patients with established cirrhosis, including patients with advanced or 
decompensated cirrhosis, such as those with a history of ascites, encephalopathy, varices and 
variceal bleeding.
Since all available randomized, placebo-controlled trials of antiviral treatment have very 
short follow-up, some have argued that the long-term clinical benefits of antiviral treatment 
and sustained virologic response (SVR) have not yet been demonstrated6. As such, some 
insurance providers and states require that significant fibrosis be present before covering 
HCV antiviral treatment7. It is therefore imperative to evaluate the long-term benefits of 
DAA-induced SVR in adequately powered and designed observational studies. DAAs have 
now led to eradication of HCV in unprecedented numbers of patients with cirrhosis and 
decompensated cirrhosis and we now have long-term follow up data, enabling us to address 
these questions8.
We hypothesized that HCV eradication may lead to a reduced risk of variceal bleeding both 
in patients with and those without pre-treatment cirrhosis during long-term follow-up. In 
patients without pre-treatment cirrhosis, HCV eradication may reduce the risk of progressing 
to cirrhosis thereby reducing the risk of developing varices and variceal bleeding. HCV 
eradication in patients with cirrhosis may stop fibrosis progression or even cause fibrosis 
regression, leading to improved portal hypertension and reduced risk of variceal bleeding9. 
Finally, HCV eradication might reduce the risk of variceal bleeding even in the highest risk 
patients, i.e. those who with known varices or variceal bleeding prior to SVR.
In this study, we used Veterans Affairs Healthcare System (VAHS) data to examine 
associations between DAA-induced HCV eradication and the risk of variceal bleeding, in 
clinically relevant subgroups such as the ones outlined above. Furthermore, we aimed to 
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investigate other characteristics that are associated with variceal bleeding in patients who 
received antiviral treatment and achieved SVR.
Methods
Data Source
The VAHS is the largest integrated healthcare provider of HCV antiviral treatment in the 
United States8. Nationwide, the VA uses a single comprehensive electronic healthcare 
information network which integrates all care applications into a single, common database. 
We obtained data on all patients who initiated antiviral therapy for chronic HCV in the VA 
system using the VA Corporate Data Warehouse (CDW), a national, continually updated 
repository of healthcare data including all patient pharmacy prescriptions, demographics, 
inpatient and outpatient visits, problem lists, procedures, vital signs, diagnostic tests, and 
laboratory tests10. The study was approved by the Institutional Review Board of the Veterans 
Affairs Puget Sound Healthcare System.
Study Population
Using VA pharmacy prescription data, we identified all DAA-only HCV antiviral regimens 
initiated in the VA from 2013 to 2015 (Figure 1). We defined sustained virologic response 
(SVR) as a serum HCV RNA viral load test below the lower limit of detection performed at 
least 12 weeks after the end of antiviral treatment11. We excluded patients with missing SVR 
data or prior liver transplant. Patients were excluded if variceal bleed, death or last follow-up 
visit occurred within the first 90 days after the start of DAA treatment. For patients who 
received multiple DAA regimens, we analyzed only the results of the first one and censored 
them at the point of a subsequent regimen that resulted in SVR, if one existed. The most 
common DAA regimen was sofosbuvir/ledipasvir (58.1%) followed by Paritaprevir/
Ritonavir/Ombitasvir/Dasabuvir (19.1%), Sofosbuvir (±daclatasvir) (13.1%), and Sofosbuvir
+Simeprevir (9.6%).
Gastrooesophageal Varices
Gastrooesophageal varices without bleeding were defined by the presence of appropriate 
diagnostic codes (ICD-9 codes 456.1, 456.21 or ICD-10 codes I85.00, I86.4 or I85.10) 
recorded at least twice. These diagnostic codes have been validated within the VA and have 
a positive predictive value of approximately 90% for identifying oesophageal varices 
compared to chart review12,13. Gastrooesophageal varices with bleeding were defined by the 
presence of appropriate diagnostic codes (ICD-9 codes 456.0, 456.20 or ICD-10 codes 
I85.10, I85.01, I86.41, or I85.11) recorded at least once. A single recording was required for 
bleeding varices (rather than two or more) because many patients may only have a single 
bleeding episode.
Nonselective beta blockers (NSBBs), frequently used to prevent variceal bleeding, were not 
included in the diagnostic criteria for gastrooesophageal varices because they have many 
other indications (hypertension, angina prophylaxis, essential tremor, migraine prophylaxis, 
post-traumatic stress disorder) and therefore were not considered specific enough. However, 
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we did evaluate NSBB as a potential confounder of the association between SVR and 
variceal bleeding.
Baseline Patient Characteristics and Potential Confounders
We collected baseline data including age, sex, race/ethnicity, diabetes, body mass index 
(BMI), HCV genotype, HCV viral load, and receipt of prior antiviral treatment. We 
extracted all clinical factors and laboratory tests [including components of the model for 
end-stage liver disease (MELD) score14] prior to treatment and recorded the value of each 
test closest to the treatment starting date within the preceding 6 months. We defined hepatitis 
B virus (HBV) coinfection by positive HBV surface antigen or viral load. We also 
determined the presence of cirrhosis, or complications of cirrhosis (ascites, spontaneous 
bacterial peritonitis, encephalopathy, gastrooesophageal varices and hepatorenal syndrome), 
type 2 diabetes mellitus, alcohol use disorders, substance use disorders, based on appropriate 
ICD-9 or ICD-10 codes recorded at least twice prior to treatment initiation in any inpatient 
or outpatient encounter. These ICD-based definitions of cirrhosis and other comorbidities 
have been widely used and validated in studies using VA medical records15–20. We assessed 
treatment with NSBBs (i.e. nadolol, propranolol or carvedilol) at the time of DAA initiation, 
since NSBBs may reduce the risk of variceal bleeding or may be associated with the 
presence of large gastrooesophageal varices or prior variceal bleeding requiring 
prophylaxis21–23.
In addition to determining the history of alcohol use disorders by ICD-9/10 codes, we used 
the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score to estimate 
the severity of alcohol use at baseline. AUDIT-C is a validated screening tool for assessing 
alcohol misuse and scores range from 0–12, with higher scores reflecting higher amounts of 
alcohol consumption24,25. Since 2004, AUDIT-C has been used to screen all veterans for 
unhealthy alcohol use annually in the outpatient setting26. Baseline alcohol use was defined 
by the AUDIT-C score reported within 1 year before initiation of antiviral treatment and 
categorized into abstinent (score of 0), low-level drinking (score of 1–3 in men, 1–2 in 
women), and unhealthy drinking (score of 4–12 in men, 3–12 in women)27,28.
Statistical Analysis
We used Cox proportional hazards regression to compare patients who achieved SVR to 
those who did not achieve SVR with respect to the risk of developing gastrooesophageal 
variceal bleeding after antiviral treatment (or, more accurately 90 days after the initiation of 
antiviral treatment). Our comparison group was DAA-treated patients who did not achieve 
SVR, rather than patients who were never treated with DAAs, to avoid the risk of health 
initiator bias (selective provision of treatments to healthy and health-conscious patients and 
avoidance of treatment of frail individuals29,30) and immortal time bias (treated patients 
experience “immortal time” prior to treatment during which outcomes cannot occur). Any 
episodes of variceal bleeding that occurred within 90 days of initiation of treatment were 
excluded because they occurred during the DAA treatment and might have caused failure of 
treatment, thus resulting in a spurious association between failure of treatment and variceal 
haemorrhage. Analyses were adjusted for the following potential confounders that may be 
associated with both SVR and the risk of progressive liver disease and variceal bleeding: 
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cirrhosis, prior history of varices, variceal bleeding, ascites, bacterial peritonitis or 
encephalopathy, age, sex, race/ethnicity, body mass index, HBV co-infection, type 2 diabetes 
mellitus, hepatocellular carcinoma, alcohol use disorders, substance use disorder, baseline 
alcohol use, NSBB use, platelet count, serum bilirubin, serum creatinine, serum albumin, 
INR, and hemoglobin levels. Continuous variables were categorized and modeled as dummy 
categorical variables.
Follow-up for development of variceal bleeding extended until 01/01/2019 so that even the 
patients treated in late 2015 (i.e. the most recent in our cohort) had adequate follow-up. 
Patients without incident variceal bleeding were censored at the time of death or last follow-
up in the VA. We presented subgroup analyses according to prior history of varices or 
variceal bleeding, cirrhosis, MELD score, FIB-4 score, and alcohol use disorders 
(suggesting comorbid alcohol-related liver disease).
Survival analyses were stratified by the Veterans Affairs facility at which the antiviral 
treatment was administered. We analyzed only the first antiviral regimen administered 
between 2013–2015. Patients who did not achieve SVR with this regimen and were 
subsequently treated again at any point up to 01/01/2019 and achieved SVR, were censored 
at the time of initiation of the regimen that led to SVR.
Results
Characteristics of study population
Patients with (n=29,998) and without SVR (n=3,584) were of similar age (61.1 vs. 60.6 
years), sex (96.6% vs. 98.1% male), and race/ethnicity (52.4% vs. 52.7% white/non-
Hispanic) (Table 1). Patients without SVR were more likely to have cirrhosis (41.1% vs. 
26.4%), non-bleeding varices (11.6% vs. 5.0%), and bleeding varices (2.9% vs. 1.4%).
There were 9,399 patients with cirrhosis, including 7,927 (84.3%) who achieved SVR and 
1,472 (15.7%) who did not achieve SVR (Table 2). Baseline demographic characteristics and 
MELD scores were similar among cirrhotic patients who did and did not achieve SVR. 
Patients without SVR had a higher proportion of complications of cirrhosis, including 
varices without bleeding (27.5% vs. 18.2%), varices with bleeding (7.1% vs. 5.1%), 
encephalopathy (28.2% vs 18.3%), and hepatocellular carcinoma (13.5% vs. 6.1%).
Association between SVR and variceal bleeding
All patients—During a mean follow-up time of 3.1 years, 549 patients developed variceal 
bleeding (incidence 0.53 per 100 patient-years) (Table 3). Among patients with SVR 
(n=29,998), 434 developed variceal bleeding (incidence 0.46 per 100 patient-years) 
compared to 115 of 3,584 patients without SVR (1.26 per 100 patient-years) and this 
difference was statistically significantly different after adjustment for baseline characteristics 
(adjusted hazards ratio [AHR] 0.66, 95% CI 0.52–0.83). SVR was also associated with a 
reduced risk of variceal bleeding in many clinically relevant sub-groups that we evaluated, 
such as patients with cirrhosis (AHR 0.73, 95% CI 0.57–0.93), without cirrhosis (AHR 0.33, 
95% CI 0.17–0.65), MELD <9 (AHR 0.41, 95% CI 0.28–0.61), alcohol use disorder (AHR 
0.65, 95% CI 0.48–0.88), and no alcohol use disorder (AHR 0.67, 95% CI 0.45–0.99).
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Patients with cirrhosis—Among 9,399 patients with cirrhosis, 480 (5.1%) developed 
variceal bleeding during 3.07 years of mean follow-up (incidence 1.66 per 100 patient 
years). The incidence of variceal bleeding was lower among those with SVR (1.55 per 100 
patient-years) compared to those without SVR (2.96 per 100 patient-years) and this 
difference remained statistically significantly after multivariable adjustment in Cox 
proportional hazards models (AHR 0.73, 95% CI 0.57–0.93) (Table 3/Figure 2).
Patients with a prior history of varices or variceal bleeding—The absolute 
incidence of variceal bleeding after antiviral treatment was much greater in patients who had 
a prior history of variceal bleeding (13.38 per 100 patient-years) or varices without bleeding 
(3.71 per 100 patient-years) than in patients who had no prior history of varices (0.20 per 
100 patient-years). Patients with SVR had a lower incidence of variceal bleeding than 
patients without SVR among those without prior varices (0.17 vs 0.56 per 100 patient-
years), with prior non-bleeding varices (3.48 vs 4.87 per 100 patient-years), and with prior 
bleeding varices (12.86 vs 16.38 per 100 patient-years) (Table 3/Figure 2). In the Cox 
proportional hazards models, the difference in variceal bleeding rate by SVR was 
statistically significant among patients without prior varices (AHR 0.52, 95% CI 0.35–0.76) 
but not among those with non-bleeding varices (AHR 0.77, 95% CI 0.52–1.15) or bleeding 
varices (AHR 0.60, 95% CI 0.33–1.09)
Characteristics associated with variceal bleeding—In the multivariable Cox 
proportional hazards model among patients with cirrhosis (Table 4), characteristics 
associated with risk of variceal bleeding included prior varices without bleeding (AHR 3.09, 
95% CI 2.39–4.00), prior varices with bleeding (AHR 9.39, 95% CI 7.08–12.46), non-
selective beta-blocker use (AHR 1.37, 95% CI 1.08–1.72), ascites (AHR 1.71, 95% CI 1.02–
2.87), spontaneous bacterial peritonitis (SBP) (AHR 2.15, 95% CI 1.31–3.52), PLT >100–
150 (AHR 4.42, 95% CI 1.08–18.07) and PLT ≤100 (AHR 6.68, 95% CI 1.64–27.17) vs 
PLT >250, and hemoglobin ≤13.6 vs >15.6 (AHR 2.12, 95% CI 1.43–3.15). Increasing 
MELD scores were associated with increased risk of variceal bleed, although this did not 
meet statistical significance for MELD 16–19 (AHR 1.31, 95% CI 0.69–2.51) or MELD >19 
(AHR 2.00, 95% CI 0.90–4.43) potentially due to fewer patients with advanced cirrhosis 
receiving DAAs. Variables associated with a decreased risk of variceal bleeding included 
SVR (AHR 0.68, 95% CI 0.53–0.86) and black/non-Hispanic race/ethnicity (AHR 0.74, 
95% CI 0.56–0.99).
Discussion
Variceal bleeding is a life-threatening complication of cirrhosis. In this large cohort of 
33,582 US Veterans who underwent DAA treatment and were followed for a mean of 3.1 
years after treatment, we extend our knowledge of the associations between SVR and 
variceal bleeding in several ways. First, we have shown that DAA-induced SVR was clearly 
associated with a reduced risk of variceal bleeding both among patients with established 
cirrhosis and among those without cirrhosis prior to antiviral treatment. Second, our results 
suggest that even among patients with a prior history of varices or variceal bleeding, which 
are the highest risk groups, DAA-induced SVR was associated with a lower risk of variceal 
bleeding (although this difference did not reach statistical significance in our multivariable 
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models). Finally, we found that although in cirrhotic patients SVR reduces the risk of 
variceal bleeding, a substantial residual risk remains and several important predictors of 
variceal bleeding are evident. Taken together, our results point to a beneficial effect of DAA-
induced SVR with regard to the potentially deadly complication of variceal bleeding and add 
to the growing literature demonstrating the clinical benefits of HCV eradication with 
DAAs31–33.
Our results demonstrate that DAAs reduced the risk of variceal haemorrhage among patients 
without cirrhosis or pre-treatment varices, underscoring the importance of “early” HCV 
treatment. Given the nature of this study, although we do not know the histological stage of 
fibrosis of the cohort, natural history studies demonstrate that, among all-comers with 
untreated HCV, cirrhosis will develop in approximately 15% over 5 years34 and, among 
patients with compensated cirrhosis, varices will occur in 7% annually35. Further, our data 
suggest the likelihood of variceal haemorrhage can be substantially reduced with early 
treatment of HCV – in our study, successful treatment of HCV prior to the development of 
cirrhosis nearly eliminated the risk of future variceal bleeding (incidence 0.07 per 100-
person years). These findings provide further support for calls to expand of HCV 
screening36 and for treatment of all patients with HCV regardless of fibrosis stage37.
We have also shown that SVR is associated with reduction in the risk of variceal bleeding 
among patients with cirrhosis, whether varices are present or not. This may be due to fibrosis 
reversion after successful DAA therapy, resulting in reduced portal pressures. Biologic 
plausibility for this is provided by studies showing that HCV treatment is associated with 
fibrosis reversion38–41, improvement in portal hypertension42–45, and decreased risk of 
oesophageal varices in compensated cirrhosis46. Not surprisingly, in our multivariable model 
low platelet count, an indirect measure of portal hypertension, and other sequelae of portal 
hypertension (e.g. ascites, SBP) were associated with an increased risk of variceal bleeding.
Despite SVR, certain patients developed variceal bleeding, including 4.8% of patients with 
pre-treatment cirrhosis. These data suggest that while some patients may have an 
improvement in portal hypertension (we speculate as a result of reduced fibrosis) with a 
concomitant reduction in the risk of variceal bleeding, this does not occur in all patients. 
This finding has several implications. First, the data suggest that there are likely highly 
specific biologic responses to SVR – leading to a reduction in portal pressure in some, but 
not all, patients. Further study to better understand these biologic responses, and the 
predictors of them, will be essential. Our multivariable model identified some known 
predictors of variceal bleeding including history of varices, other decompensation events, 
and low platelet count. NSBB use was also associated with an increased risk of variceal 
bleeding, as expected since these medications are preferentially used in patients with high-
risk varices (e.g. large, red wale signs). Lastly, black race was associated with a lower risk of 
variceal bleeding, which has previously been reported and deserves more study47. Second, it 
suggests that it is important to continue endoscopic surveillance for varices and prophylaxis 
for variceal bleeding if indicated following SVR. This was particularly true among patients 
with pre-treatment varices. Conversely, it may be that cirrhosis patients without varices who 
achieve SVR may be able to safely receive screening endoscopies less frequently than every 
2–3 years, as is currently recommended by the American Association for the Study of Liver 
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Diseases (AASLD)48. Future prospective and cost-effectiveness studies could help answer 
these questions.
This study is strengthened by its large, geographically distributed cohort of HCV patients 
with prolonged follow-up after treatment with DAAs. However, this study has some 
potential limitations. First, all patients were derived from a single, national healthcare 
system with fairly uniform antiviral treatment practices and guidelines across its facilities. 
Second, data were derived from the national VA healthcare system where male sex 
predominates. Third, since this is by necessity an observational study, we cannot exclude the 
possibility that residual confounding may have contributed to the associations we observed 
between SVR and variceal haemorrhage. However, the associations persisted after careful 
adjustment for >20 baseline characteristics known or suspected to be associated with SVR 
and variceal bleeding.
In conclusion, these findings demonstrate that successful treatment of HCV with DAAs is 
associated with a reduced risk of subsequent variceal bleeding. This provides further 
evidence supporting the real-world benefits of DAAs in patients with and without cirrhosis 
and emphasizes the importance of early identification and treatment of HCV-infected 
patients.
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Abbreviations:
AASLD American Association for the Study of Liver Diseases
AHR adjusted hazards ratio
AUDIT-C Alcohol Use Disorders Identification Test-Consumption
BMI body mass index
CDW Corporate Data Warehouse
DAA direct acting antiviral
HBV hepatitis B virus
HCV hepatitis C virus
ICD International Classification of Diseases
INR international normalized ratio
MELD model for end-stage liver disease
NSBBs nonselective beta blockers
SBP spontaneous bacterial peritonitis
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SVR sustained virologic response
VAHS Veterans Affairs Healthcare System
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Figure 1. Flow diagram of HCV patients included in our analysis cohort
Our cohort included all DAA-treated patients within the national VA from 2013–2015, 
excluding those with missing data, prior liver transplant, or variceal bleed, death or liver 
transplant within 90 days of DAA treatment. Of our resulting cohort of 33,582 patients, 
29,998 (89.3%) had SVR and 3,584 (10.6%) had no SVR. Patients were followed for a mean 
of 3.1 years to assess for the development of variceal bleeding.
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Figure 2. Cumulative incidence curves among patients with SVR versus no SVR by presence of 
cirrhosis, varices and variceal bleeding
The cumulative incidence of variceal haemorrhage among patients with and without 
sustained virologic response (SVR) after direct acting antiviral (DAA) treatment for hepatitis 
C virus (HCV) in (a) patients with cirrhosis, (b) patients without prior cirrhosis, (c) patients 
with prior varices, and (d) patients with prior variceal bleed.
Moon et al. Page 13

























Moon et al. Page 14
Table 1.
Baseline characteristics of HCV-infected patients who received antiviral treatment with DAAs from 2013–
2015, according to whether they achieved SVR
No SVR (n=3,584) SVR (n=29,998) P-value
Age, yrs (mean [SD]) 60.6 [6.6] 61.1 [6.5] < 0.001
BMI, (mean [SD]) 28.7 [5.8] 28.1 [5.4] < 0.001
Male (%) 98.1 96.6 < 0.001
Race/Ethnicity (%) < 0.001
White, non-Hispanic 52.7 52.4
Black, non-Hispanic 30.6 33.1
Hispanic 7.4 5.2
Other 2 1.7
Declined to answer/missing 7.3 7.8
Non-Genotype 1 (%) 28.2 14.7 < 0.001
HBV co-infection(%) 0.8 1.3 0.01
Cirrhosis (%) 41.1 26.4 < 0.001
Varices (%) < 0.001
No varices 85.5 93.6
Varices, but no bleeding 11.6 5.0
Varices with bleeding 2.9 1.4
Ascites (%) 0.6 0.3 < 0.01
Encephalopathy (%) 13 6.3 < 0.001
Hepatocellular Carcinoma (%) 6.7 2 < 0.001
Diabetes (%) 32.9 29 < 0.001
Non-selective beta blocker (%) 10.6 7.9 < 0.001
AUDIT-C scores* (%) 0.09
Abstinent 67.2 66.2
Low-level use 22.4 24
Unhealthy use 10.4 9.8
Alcohol Use Disorder (%) 50.3 44 < 0.001
MELD score ≥ 9 25.2 19.4 < 0.001




> 2 33.5 30.3
Laboratory Results (mean [SD])
Alpha Fetoprotein, ng/mL 7.3 [4.7] 6.2 [4.3] < 0.001
Hemoglobin, g/dL 14.3 [1.7] 14.5 [1.6] < 0.001
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No SVR (n=3,584) SVR (n=29,998) P-value
Platelet Count, k/μL 155.8 [74.1] 178.6 [70.6] < 0.001
Creatinine, mg/dL 1.0 [0.5] 1.0 [0.5] < 0.01
Bilirubin, g/dL 0.8 [0.6] 0.7 [0.5] < 0.001
Albumin g/dL 3.7 [0.6] 3.9 [0.5] < 0.001
INR 1.2 [0.9] 1.2 [0.9] 0.42
FIB-4 5.3 [13.6] 3.9 [16.5] < 0.001
MELD 8.6 [3.3] 8.3 [3.4] < 0.001
DAA = direct acting antivirals, HBV = hepatitis B virus, IFN = interferon, INR = international normalized ratio, MELD = model for end-stage liver 
disease, SVR = sustained virologic response
*
Abstinent from alcohol: AUDIT-C score 0. Low-level alcohol use: AUDIT-C 1–3 in men, 1–2 in women. Unhealthy alcohol use: AUDIT-C 4–12 
in men, 3–12 in women
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Table 2.
Baseline characteristics of HCV-infected patients with cirrhosis who received antiviral treatment with DAAs 
from 2013–2015, according to whether they achieved SVR or not
No SVR (n=1,472) SVR (n=7,927) P-value
Age, yrs (mean [SD]) 61.3 [5.4] 62.0 [5.3] < 0.001
BMI, (mean [SD]) 29.4 [5.9] 28.7 [5.5] < 0.001
Male (%) 98.7 97 < 0.001
Race/Ethnicity (%) < 0.001
White, non-Hispanic 55.9 53.8
Black, non-Hispanic 24.5 29.2
Hispanic 9.7 7.5
Other 2.1 1.8
Declined to answer/missing 7.8 7.7
Non-Genotype 1 (%) 27.7 12.9 < 0.001
HBV co-infection(%) 0.7 1.8 < 0.01
Varices (%) < 0.001
No varices 65.4 76.6
Varices, but no bleeding 27.5 18.2
Varices with bleeding 7.1 5.1
Ascites (%) 1.4 1 0.2
Encephalopathy (%) 28.2 18.3 < 0.001
Hepatocellular Carcinoma (%) 13.5 6.1 < 0.001
Diabetes (%) 38.2 37.9 0.79
Non-selective beta blocker (%) 19.2 16.6 0.02
AUDIT-C scores* (%) 0.44
Abstinent 75.3 74.5
Low-level use 17.1 18.3
Unhealthy use 7.6 7.1
Alcohol Use Disorder (%) 52.9 48 < 0.001
MELD score ≥ 9 39.5 31.5 < 0.001




> 2 46.9 45.6
Laboratory Results (mean [SD])
Alpha Fetoprotein, ng/mL 8.5 [4.7] 7.7 [4.6] < 0.001
Hemoglobin, g/dL 13.9 [1.7] 14.0 [1.7] < 0.01
Platelet Count, k/μL 109.7 [56.7] 130.7 [63.9] < 0.001
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No SVR (n=1,472) SVR (n=7,927) P-value
Creatinine, mg/dL 0.9 [0.5] 1.0 [0.5] < 0.01
Bilirubin, g/dL 1.1 [0.8] 0.9 [0.7] < 0.001
Albumin g/dL 3.4 [0.6] 3.6 [0.5] < 0.001
INR 1.3 [1.0] 1.3 [1.2] 0.7
FIB-4 8.6 [20.5] 7.3 [29.9] 0.11
MELD 9.6 [3.6] 9.2 [3.8] < 0.001
DAA = direct acting antivirals, HBV = hepatitis B virus, IFN = interferon, INR =international normalized ratio, MELD = model for end-stage liver 
disease, SVR = sustained virologic response
*
Abstinent from alcohol: AUDIT-C score 0. Low-level alcohol use: AUDIT-C 1–3 in men, 1–2 in women. Unhealthy alcohol use: AUDIT-C 4–12 
in men, 3–12 in women
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Table 3.





















No SVR 3,584(10.7) 2.5 115(3.2) 1.26 1 1
SVR 29,998(89.3) 3.1 434(1.4) 0.46 0.38(0.31–0.47) 0.66(0.52–0.83)
No prior varices
No SVR 3,064(9.8) 2.6 45(1.5) 0.56 1 1
SVR 28,070(90.2) 3.2 152(0.5) 0.17 0.31(0.22–0.43) 0.52(0.35–0.76)
Prior Varices 
without Bleeding
No SVR 416(21.7) 2.1 42(10.1) 4.87 1 1
SVR 1,502(78.3) 3.0 155(10.3) 3.48 0.69(0.48–0.99) 0.77(0.52–1.15)
Prior variceal 
bleeding
No SVR 104(19.6) 1.6 28(26.9) 16.38 1 1
SVR 426(80.4) 2.3 127(29.8) 12.86 0.76(0.47–1.23) 0.60(0.33–1.09)
Cirrhosis
No SVR 1,472(15.7) 2.2 98(6.7) 2.96 1 1
SVR 7,927(84.3) 3.1 382(4.8) 1.55 0.55(0.44–0.69) 0.73(0.57–0.93)
No Cirrhosis
No SVR 2,112(8.7) 2.7 17(0.8) 0.29 1 1
SVR 22,071(91.3) 3.1 52(0.2) 0.07 0.26(0.15–0.45) 0.33(0.17–0.65)
MELD < 9
No SVR 2,106(9.8) 2.7 43(2.0) 0.76 1 1
SVR 19,487(90.2) 3.2 136(0.7) 0.22 0.28(0.20–0.40) 0.41(0.28–0.61)
MELD ≥ 9
No SVR 1,204(13.2) 2.3 67(5.6) 2.45 1 1
SVR 7,889(86.8) 3.0 277(3.5) 1.15 0.50(0.38–0.66) 0.77(0.57–1.04)
Alcohol use 
disorder
No SVR 1,802(12.0) 2.5 70(3.9) 1.53 1 1
SVR 13,187(88.0) 3.1 236(1.8) 0.57 0.38(0.29–0.50) 0.65(0.48–0.88)
No alcohol use 
disorder
No SVR 1,782(9.6) 2.5 45(2.5) 0.99 1 1
SVR 16,811(90.4) 3.2 198(1.2) 0.37 0.38(0.28–0.53) 0.67(0.45–0.99)
*
Adjusted for cirrhosis, prior history of varices, variceal bleeding, ascites, bacterial peritonitis or encephalopathy, age, sex, race/ethnicity, body 
mass index, HBV co-infection, type 2 diabetes mellitus, hepatocellular carcinoma, alcohol use disorders, AUDIT-C score, non-selective beta 
blocker, substance use disorder, Charlson Comorbidity Index, platelet count, serum bilirubin, serum creatinine, serum albumin, INR and blood 
hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables; MELD = model for end-stage 
liver disease, SVR = sustained virologic response
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Table 4.
Characteristics associated with variceal bleeding in patients with cirrhosis following DAA-based antiviral 
treatment
Variceal bleeding incidence per 100 patient-years Adjusted* hazard ratio (95% CI)
No SVR 2.96 1
SVR 1.55 0.68(0.53–0.86)
No Prior Varices 0.64 1
Prior Varices without bleeding 3.66 3.09(2.39–4.00)
Prior varices with bleeding 13.92 9.39(7.08–12.46)



























White, non-Hispanic 2.07 1
Black, non-Hispanic 1.01 0.74(0.56–0.99)
Hispanic 2.22 0.95(0.67–1.36)
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Variceal bleeding incidence per 100 patient-years Adjusted* hazard ratio (95% CI)
Other 1.77 0.79(0.39–1.57)
Declined to answer/missing 1.46 0.86(0.58–1.28)
BMI
<25 1.58 1
25-< 30 1.97 1.28(0.99–1.66)
30-< 35 1.52 1.08(0.81–1.45)
≥35 1.53 1.00(0.70–1.41)
*
Adjusted by Cox proportional hazards regression for all the characteristics shown in the Table
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